A-Share · Pre-Market
A-Share Pre-Market Brief | 2026-11-16 (Monday)
Machine-translated from the Chinese original. In case of any discrepancy, the Chinese version prevails.
Single-name entries 15
Show 3 more
Scores are a subjective ordinal scale; gaps within a band carry no ranking meaning
Time window: after the close on Friday 2026-11-13 at 15:00 → 2026-11-16 07:30. Friday's recap see
reports/a-share/2026-11-13-recap.md(ice point: ChiNext -3.32%, nearly 4,500 decliners, limit-up advancement rate only 19%). Friday close: Shanghai Composite 3634.35 (-0.59%), ChiNext 2426.08 (-3.32%).
0. Today's One-Line Summary
The single hardest new catalyst of the weekend is the landing of the medical-insurance "dual catalogues" (51 first-class innovative drugs, a record high; CAR-T entering medical insurance for the first time; 19 A-share pharma companies disclosing concentratedly on the evening of 11-15), superimposed on the macro warmth from the first meeting of the trade council under the China-US economic and trade consultation mechanism (11-13), which — against Friday's ice point — creates the opening conditions for a "news-driven rebound"; but the overseas computing-power chain is the biggest headwind — NVIDIA CEO Jensen Huang resigned on 11-12 and the stock fell -13% for the full week, SOX -3.43% on Friday, AMD down over 8%, and with NVDA earnings due this Tuesday (US Eastern 11-17), funds will most likely keep de-risking into it, so A-share computing hardware such as optical modules / PCB / memory remains under pressure on Monday. Driver types: policy (medical insurance) + overseas industry (NVIDIA event, negative) + orders (Yuanjie RMB 1.744 billion) + event (Iran's 11-15 attack on the US military base in Bahrain). Likely fund destinations: innovative drugs (new catalyst + oversold low position), oil & gas defense (event + dividends, the only validated direction on Friday), gaming / AI short drama (Friday's only survivor + BLG's championship fermenting over the weekend). Pre-market state judgment: a lower or flat open is most likely; the strength of the rebound hinges on auction absorption in innovative drugs and whether the Shanghai Composite can reclaim 3647; do not chase a reflexive bounce in the computing-power chain — treat the first positive candle after the ice point purely as an observation window.
1. News Overview
| No. | Time | Source | Title | Type | Branch | Impact | Link |
|---|---|---|---|---|---|---|---|
| 1 | 11-14 | National Healthcare Security Administration / Qiushi | 2026 medical insurance + commercial insurance innovative-drug "dual catalogues" released: 107 additions, 51 first-class innovative drugs a record high; 2 commercial-insurance drugs moved into basic medical insurance | Policy | Innovative drugs | S- | Qiushi.com |
| 2 | 11-15 evening | Company announcements | 19 A-share pharma companies disclosed concentratedly products included/renewed (恒瑞医药 (Hengrui Medicine): 3 first-time inclusions + 7 renewals; 百利天恒 (Baili Tianheng): iza-bren included in its first launch year; 君实 (Junshi) Touyi new indication, etc.) | Announcement | Innovative drugs | A | JRJ |
| 3 | 11-13 evening | Company announcement | 源杰科技 (Yuanjie Technology, 688498) won a RMB 1.744 billion high-power laser-diode chip order from Customer B (ex-tax) | Orders | Optical chips | A | CLS |
| 4 | 11-12~15 | Reuters / Caixin et al. | Jensen Huang resigned as NVIDIA CEO/president/director; CFO takes over on an interim basis; NVIDIA -13% for the week (largest weekly drop since April 2025), down six consecutive weeks; employee petition for his return; Asian supply-chain worries brewing | Overseas industry (negative) | Computing-power chain / semiconductors | A (negative) | TMTPost、JW View (US close) |
| 5 | 11-13 (Friday) | US close | Dow +0.10%, S&P -0.40%, Nasdaq -0.91%; SOX -3.43%, AMD -8%, SanDisk/WDC -5%, Broadcom/ARM -4% | Overseas (negative) | Semiconductors / storage / computing power | A (negative) | Jin10 |
| 6 | 11-15 | CCTV / The Paper | Iran's Revolutionary Guard 6 drones attacked the radar of the US military base in Riffa, Bahrain; Iran warned of expanding strikes to US bases in Europe; Bahrain intercepted multiple aerial targets | Event | Oil & gas / oil shipping / defense | A | The Paper、CLS |
| 7 | 11-13 | Ministry of Commerce | First meeting of the trade council under the China-US economic and trade consultation mechanism: discussions on tariffs, "USD 30 billion vs 30 billion" reciprocal tariff cuts, agricultural trade exchanges | Macro | Broad market / export chain / rare earths | A | CLS weekend roundup |
| 8 | 11-15 | Company announcement | 中国稀土 (China Rare Earth, 000831) plans to issue shares to buy 51% of Zhongxi (Liangshan) Rare Earth (issue price RMB 39.41/share); resumes trading 11-16; target asset is the Maoniuping rare earth mine, whose 2025 net profit of RMB 819 million is 4.75x the listed company's | Restructuring | Rare earths | B+ | Company announcement (via NBD) |
| 9 | 11-15 | Company announcement | TCL 中环 (TCL Zhonghuan, 002129) plans to acquire 65.8% of Zhonghuan Advanced (No. 1 in China in semiconductor silicon wafer shipments/revenue); resumes trading 11-16 | Restructuring | Semiconductor silicon wafers | B | CLS |
| 10 | 11-15 | Company announcement | 游族网络 (Yoozoo Network, 002174) subsidiary won a RMB 1.428 billion flash-memory particle procurement order; announcement explicitly states "revenue recognized on a net basis, negligible impact on current-period revenue" | Orders (cooling) | Storage trading | B | 10jqka |
| 11 | 11-15 early morning | Riot Games / media | BLG beat GEN 3:1 to win the League of Legends S16 championship; LPL champions again after five years, "one run through four" LCK teams; Bilibili giving all members premium membership | Event | Gaming / esports / media | B+ | Eastmoney |
| 12 | 11-14 | CINNO (via CLS) | December TV panel structural slight price increase: 55-85 inch panels up USD 1-2, other sizes flat | Pricing | Panels | C+ | CLS weekend roundup |
| 13 | 11-14 | NDRC / National Energy Administration | "15th Five-Year" new-type energy storage implementation plan: guiding storage battery companies to build capacity rationally and orderly, guarding against blind expansion | Policy (bearish) | Energy storage / lithium batteries | B (negative) | CLS weekend roundup |
| 14 | 11-14 | CSRC | Wu Qing: deepen research on the long-term market-stability mechanism; study and evaluate quantitative trading, share-reduction and other system optimizations | Regulation | Broad-market sentiment | B (warm) | CLS weekend roundup |
| 15 | 11-16 publication | Qiushi | Xi Jinping's "Building an Asia-Pacific Community with a Shared Future"; APEC CEO Summit with 115 Fortune Global 500 companies participating, US firms nearly 20% of foreign participants | Macro | Broad market / going global | B | CLS weekend roundup |
| 16 | announced 11-03 / effective 11-15 | PBOC | FX reserve requirement ratio 4%→6% (announced 11-03, effective 11-15, to dampen RMB appreciation expectations; limited direct impact on A-share liquidity); RMB 200 billion outright reverse repo rolled at a smaller size (net drain of RMB 100 billion); October M2 +7.1% (October data) | Liquidity | Broad market | B (neutral) | CLS weekend roundup |
| 17 | 11-14 | Shanghai Stock Exchange | Key monitoring of high-premium funds such as the global-chip LOF; self-disciplinary measures on 95 abnormal trading cases | Regulation | Chips / sentiment | B (negative) | CLS weekend roundup |
| 18 | 11-15 | Company announcement | 天普股份 (Tianpu, 605255, 4 consecutive limit-ups) suspended for verification from 11-16; 金辰股份 (Jinchen, 603396, 3 limit-ups) risk warning: unrelated to reports about SINGULUS SOLAR, no substantive business dealings | Regulation / sentiment | Short-term height | B (negative) | CLS weekend roundup |
| 19 | 11-14 | Caixin Weekly | Over the week to 11-13, WTI/Brent fell 14%-18% from end-October; global crude supply back in surplus; after the 11-15 attack, Brent grey market only +0.38% (Friday intraday USD 93.99) | Pricing (negative) | Oil & gas | B (negative) | Caixin Weekly |
| 20 | 11-14 | Industry | China's 10-tonne-class electric commercial aircraft CE-25A made its first crewed flight (COMAC + CATL et al.); SpaceX Starship's first "chopsticks-catching" (upper stage) success | Event | Low-altitude / commercial spaceflight | C | CLS weekend roundup |
| 21 | 11-14 | US Labor Department | US October PPI +6.5% YoY, below the 6.6% expected (sticky inflation; limited guidance for the Fed's rate-cut path) | Macro | US stocks / US Treasuries | C | CLS weekend roundup |
| 22 | 11-14 | Silver Institute | Global silver supply to run a deficit for a sixth consecutive year (gap of 35 million oz), but photovoltaic silver demand expected to fall 21% | Pricing | Silver | C | CLS weekend roundup |
| 23 | 11-13 | Company announcement | 天孚通信 (Tianfu Communication, 300394) cumulatively bought back 500,000 shares for RMB 65.50 million (to be cancelled) | Announcement | Optical communications | C | Jiemian |
Note: item 15's release time is "11-16 publication" (Qiushi magazine); all other items are within the time window.
2. Strongest Positive Branches, Descending
| Rank | Branch | Strength | Core news | Logic hardness | Durability | Beneficiary path | Representative stocks | Risks |
|---|---|---|---|---|---|---|---|---|
| 1 | Innovative drugs (medical-insurance dual catalogues) | ★★★★☆ | 51 first-class innovative drugs into medical insurance a record high, CAR-T entering medical insurance for the first time, 19 A-share pharma companies disclosing concentratedly | Hard (official catalogue + company announcements, double confirmation) | Medium (effective 2027-01-01; short-term sentiment-driven, mid-term hinges on volume-for-price) | Payment-side expansion → volume; BD going-global logic strengthened | 恒瑞医药 (600276) 、百利天恒 (688506) 、君实生物 (688180) 、复星医药 (Fosun Pharma, 600196) | Inclusion = price cuts, almost no current-period earnings contribution; profit-taking on Monday's gap-up; reimbursement scope generally narrowed |
| 2 | Oil & gas defense (Middle East event + dividends) | ★★★★ | Iran's 11-15 attack on the US military base in Bahrain, escalation | Medium (event real, but oil prices muted: grey market only +0.38% after the attack, against a supply-surplus backdrop) | Short-medium (event position, exit on ceasefire) | Oil prices / risk aversion → production dividend defense + oil-shipping elasticity | 中国海油 (CNOOC, 600938) 、中远海能 (COSCO Shipping Energy, 600026) 、中海油服 (COSL, 601808) | Oil prices already fell 14-18% over two weeks, muted geopolitical transmission; exit as soon as the event de-escalates |
| 3 | Gaming / esports / AI short drama (running theme) | ★★★☆ | BLG wins S16 championship (LPL champions again after five years), fermenting across the internet over the weekend; Friday's AI short drama / cinema was the only survivor on the ice-point day | Medium (sentiment hard, earnings chain long) | Short (sentiment theme; watch low-position 1-to-2 ladder) | Event heat → gaming attention + esports derivatives; AI comic-drama cost-reduction narrative | 恺英网络 (Kaiying Network, 002517) 、文投控股 (Wentou Holdings, 600715, high-flag risk) 、金逸影视 (Jinyi Cinema, 002905) 、横店影视 (Hengdian Entertainment, 603103) | Overall leader Wentou Holdings 18 days 10 limit-ups has itself disclosed AI comic-drama revenue share of only ~2.57%; high-position relay in a sentiment ebb = catching the falling knife |
| 4 | Optical chips (Yuanjie's big order) | ★★★ | Yuanjie's RMB 1.744 billion order ≈ 108% of 9M26 revenue | Hard (company announcement) | Medium (delivery mostly after 2027) | Direct order → earnings elasticity; high-power CW/EML benefiting from AI optical modules | 源杰科技 (688498) | Friday single-day -11.76%, PE (TTM) ~75x, anonymous Customer B, optical-communication sector in third day of ebb |
| 5 | Rare earths (restructuring + China-US) | ★★☆ | China Rare Earth resumes trading to acquire 51% of Zhongxi (Liangshan) (target 2025 net profit RMB 819 million); first trade-council meeting continues | Medium (announcement real, pricing undetermined) | Medium (injection landing; export-control suspension expired 11-10, resumption uncertain either way) | Asset injection accretion + rare-earth price cycle | 中国稀土 (000831) 、北方稀土 (Northern Rare Earth, 600111) | PE (TTM) ~130x; if rare-earth prices fall, target-earnings estimates must be cut; most likely one-way sealed / excessive gap-up |
| 6 | Semiconductor silicon wafers (Zhonghuan resumes) | ★★ | TCL Zhonghuan acquires 65.8% of Zhonghuan Advanced (No. 1 in China in wafers) | Medium (announcement real, but small accretion) | Medium | Minority stake consolidated into parent, direction positive | TCL 中环 (002129) | PV main business 9M26 loss of RMB 4.557 billion, debt ratio 73.4%; good news drowned by losses |
| 7 | Panel price increases | ★★ | CINNO: December 55-85 inch panels up USD 1-2 | Medium (institution forecast) | Weak (small magnitude) | Expectation of price-hike letters landing | 京东方 A (BOE A, 000725) 、 TCL 科技 (TCL Technology, 000100) | Increase of USD 1-2 per panel, limited elasticity; continuation of old news, not a new catalyst |
| 8 | Low-altitude / commercial spaceflight / silver / AI home appliances | ★ | CE-25A first flight, Starship chopsticks catch, silver deficit, AI home appliances in introduction phase | Weak (remote mapping / weak data) | Weak | Concept mapping | — | High probability of a one-day pop, do not chase |
Branch notes: why Innovative drugs ranks first — it is the only new catalyst of the weekend with "official document + batch of company announcements" double confirmation, and the sector was previously oversold (pharma was still being sold on Friday), with enough capacity for large funds; but do remember the catalogue takes effect only in 2027, so Monday's move is essentially a valuation repair on "access certainty + payment expansion", not current earnings — the risk of a gap-up-then-fade is real. Oil & gas ranks second because it was the only direction validated by funds on Friday (CNOOC +2.05%, COSL +0.41%), and the weekend escalation gave it continuity, but muted oil prices (grey market +0.38% after the attack, supply surplus) mean it can only be a defensive position, not an offensive one. Gaming / short drama is a "running theme" — Friday's recap lesson requires covering already-running ladders pre-market: Wentou Holdings (600715) with 10 limit-ups in 18 days is a sentiment-top signature; branch opportunities lie in low-position 1-to-2 moves and real-earnings gaming catch-ups, not at high positions. Optical chips is a typical "single-stock logic vs sector headwind" gamble; no matter how real Yuanjie's order is, the auction must confirm whether funds pick the stock or kill the sector. Sector distribution: innovative drugs concentrated on the main board (Hengrui/Fosun) and STAR Market (Baili Tianheng/Junshi/Heyuan, mind the -U unprofitable flag); oil & gas all main board; gaming mostly main board; optical chips / silicon wafers are high-volatility STAR/ChiNext names; no key Beijing Stock Exchange targets today.
3. Stock Positive-Strength Overall Ranking
| Rank | Code | Name | Board | Branch | Level | Score | Core news | Path | Directness | Fundamentals / industry position | Expectation gap | Technicals / sentiment | Risks | Conclusion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 600276 | 恒瑞医药 | Shanghai main board | Innovative drugs | A | 69 | 3 first-time inclusions + expanded indications + 7 renewals (involving drugs with RMB 6.951 billion 2025 sales) | Access → volume | Direct (but effective 2027) | Absolute innovative-drug leader, 9M26 net profit +20.4%, cash RMB 43.4 billion, debt ratio 12% | Medium (mostly priced in) | Oversold + large institutional capacity | Static PE ~41x; profit-taking on gap-up | priority deep-dive |
| 2 | 688498 | 源杰科技 | STAR Market (±20%) | Optical chips | A | 65 | RMB 1.744 billion order ≈ 108% of 9M26 revenue | Direct order → earnings | Direct | Scarce optical-chip IDM leader, 9M26 revenue +320% / net profit +867% | Medium (Customer B identity + delivery cadence undetermined) | Friday -11.76% plunge before the good news, huge disagreement | PE (TTM) ~75x; sector ebb; anonymous customer | watch closely (auction decides) |
| 3 | 600938 | 中国海油 | Shanghai main board | Oil & gas | A- | 63 | Middle East escalation + Brent USD 94 + TTM dividend yield ~4.2% | Oil-price elasticity + defense | Indirect (earnings already materializing, event kicker) | Low-cost leader, 9M26 net profit +16.8%, PE (TTM) ~10.5x | Low-medium (already +2.05% on Friday) | Only big-cap volume gain closing green on Friday's ice-point day | Supply surplus, oil-price pullback | priority deep-dive (defense) |
| 4 | 000831 | 中国稀土 | Shenzhen main board | Rare-earth restructuring | A- | 62 | Acquiring 51% of Zhongxi (Liangshan), target 2025 net profit RMB 819 million (4.75x the listed company) | Asset injection accretion | Direct (pricing TBD) | Medium/heavy rare-earth smelting & separation platform, 9M26 net profit +112%; debt ratio only 9.8% | Medium (valuation/pricing not out) | Resuming after 2-week suspension, most likely one-way sealed / big gap-up | PE (TTM) ~130x; rare-earth price cycle | watch closely (watch only if gap-up too large) |
| 5 | 688506 | 百利天恒 | STAR Market (±20%) | Innovative drugs | A- | 57 | iza-bren, world's first bispecific ADC, included in medical insurance in its first launch year; BMS license up to USD 8.4 billion | Access catalyst + BD monetization | Indirect (earnings variable hinges on BMS milestones) | Top-tier global FIC pipeline; but 9M26 operating cash flow -RMB 2.168 billion, debt ratio 59.1% | Medium (narrow indication scope) | Highest-elasticity innovative-drug target | Unprofitable, fast cash burn, market cap RMB 103.2 billion | watch closely |
| 6 | 002517 | 恺英网络 | Shenzhen main board | Gaming | B+ | 57 | BLG championship + "Blazing Awakening" contributing ~RMB 3.2 billion revenue in 9M26 | Sentiment + real earnings | Indirect | Real gaming earnings: 9M26 revenue +78% / net profit +31%, PE (TTM) ~14x | Medium (Friday -1.9%, unmoved) | Gaming catch-up position, cash flow RMB 2 billion | Single hit title ~44% of revenue (estimate); Q3 revenue up but profit not | watch closely |
| 7 | 600026 | 中远海能 | Shanghai main board | Oil shipping | B+ | 56 | Middle East escalation → VLCC rate risk premium | Rate elasticity | Direct (event-sensitive) | One of the world's largest tanker fleets, 9M26 net profit +172%, PE (TTM) ~10.3x | Medium (already -2.21% and abandoned on Friday) | Elasticity position, unvalidated Friday | Rate pullback from highs risk; debt ratio 47.7%; needs double confirmation | watch only |
| 8 | 688180 | 君实生物 | STAR Market (±20%) | Innovative drugs | B+ | 54 | Touyi: all 13 indications included in medical insurance (most complete domestic PD-1 coverage) | Volume-for-price continuation | Direct (materializing) | 9M26 revenue +39%, loss narrowing, operating cash flow turned positive | Low-medium | Loss-making stock, weaker elasticity than Baili | Still loss-making; debt ratio 59.6% | watch only |
| 9 | 601808 | 中海油服 | Shanghai main board | Oilfield services | B+ | 48 | Offshore oilfield services, benefiting from industry capex | Day-rate transmission | Indirect (longest chain) | 9M26 net profit only +0.7%, cash flow weakening | Low | Friday +0.41% resilient | Revenue up but profit not; dividend yield only ~2.3% | watch only |
| 10 | 600196 | 复星医药 | Shanghai main board | Innovative drugs | B | 45 | 5 drugs included (Hanshuang first inclusion); involved drugs 2025 sales RMB 2.234 billion (~5% of revenue) | Access → moderate volume | Indirect (elasticity diluted) | PE ~18x, PB ~1.2x; goodwill RMB 10.76 billion | Low | Low-valuation defensive position | Goodwill impairment; tight short-debt structure | watch only |
| 11 | 002129 | TCL 中环 | Shenzhen main board | Semiconductor silicon wafers | B | 45 | Acquiring 65.8% of Zhonghuan Advanced (No. 1 in China in wafers) | Parent-net-profit accretion | Indirect (small magnitude) | PV main business 9M26 loss of RMB 4.557 billion, debt ratio 73.4% | Low | Resumption event | Good news drowned by main-business losses; dilution | watch only |
| 12 | 002555 | 三七互娱 | Shenzhen main board | Gaming | B | 43 | BLG championship sentiment mapping | Sentiment | Indirect | Leader but 9M26 ex-non-recurring ~-47%, Q3 single-quarter loss | Low | Weakening trend | User-buying model under pressure; cash flow -60% | watch only |
| 13 | 688765 | 禾元生物 | STAR Market (-U unprofitable, ±20%) | Innovative drugs | B | 37 | World's first rice-derived recombinant human albumin included in medical insurance | 0-to-1 access | Direct but negligible magnitude | 9M26 revenue only RMB 28 million; cash runway to be validated | Low (already +8.8% front-running Friday) | High-expectation small cap | No current earnings; continued losses | watch only |
| 14 | 002174 | 游族网络 | Shenzhen main board | Storage trading + gaming | C+ | 32 | RMB 1.428 billion flash order (net method) + gaming attribute | Buy-sell spread | Extremely weak (announcement self-cooling) | Main business 2025 loss of RMB 347 million, Q3 single-quarter loss RMB 111 million, 9M cash flow -RMB 650 million | Medium (dual concept easily speculated) | Concept mash-up | Advance-payment trading risk; consecutive losses | Pass |
| 15 | 002148 | 北纬科技 | Shenzhen main board | Gaming / communications | C | 20 | 3-limit-up height flag (gaming label) | Pure sentiment | None | 9M26 net profit only RMB 5.92 million, PE (TTM) ~7700x (Tencent quote basis, market cap RMB 4.44 billion / TTM net profit ~RMB 5.76 million), negative cash flow | Low | Height banner after Tianpu's suspension | Q3 profit -60%; relay = catching the knife | Pass (sentiment weathervane only) |
Not on the list but worth knowing: Wentou Holdings (600715, 10 limit-ups in 18 days, sentiment top, watch only), Jinchen (603396, risk-warning announcement, Pass), Tianpu (605255, suspension verification), Northern Rare Earth (600111, rare-earth follow-on), Jinyi Cinema (002905) / Hengdian Entertainment (603103) / China Film (600977, low-position 1-to-2 cinema watch pool).
4. Stock Scoring Model
Total 100 = news-source authority (0-15) + directness of benefit (0-20) + earnings elasticity (0-15) + industry position & fundamentals (0-15, SEPA reference: revenue / net profit / gross margin / cash flow / debt ratio / moat / niche leadership) + expectation gap (0-10) + theme durability (0-10) + A-share trading attributes (0-10) - risk deduction (0-15).
| Rank | Name (Code) | Source authority | Directness | Earnings elasticity | Position / fundamentals | Expectation gap | Theme durability | Trading attributes | Risk deduction | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 恒瑞医药(600276) | 15 | 14 | 12 | 12 | 5 | 8 | 7 | -4 | 69 |
| 2 | 源杰科技(688498) | 15 | 18 | 13 | 11 | 6 | 6 | 6 | -10 | 65 |
| 3 | 中国海油(600938) | 12 | 12 | 10 | 12 | 5 | 7 | 8 | -3 | 63 |
| 4 | 中国稀土(000831) | 15 | 14 | 11 | 11 | 6 | 6 | 6 | -7 | 62 |
| 5 | 百利天恒(688506) | 15 | 11 | 10 | 9 | 6 | 7 | 6 | -7 | 57 |
| 6 | 恺英网络(002517) | 13 | 8 | 8 | 12 | 6 | 6 | 8 | -4 | 57 |
| 7 | 中远海能(600026) | 12 | 12 | 11 | 10 | 5 | 6 | 7 | -7 | 56 |
| 8 | 君实生物(688180) | 15 | 12 | 9 | 7 | 5 | 6 | 6 | -6 | 54 |
| 9 | 中海油服(601808) | 12 | 9 | 7 | 8 | 4 | 6 | 6 | -4 | 48 |
| 10 | 复星医药(600196) | 15 | 8 | 6 | 7 | 4 | 5 | 5 | -5 | 45 |
| 11 | TCL 中环(002129) | 15 | 9 | 6 | 6 | 5 | 6 | 6 | -8 | 45 |
| 12 | 三七互娱(002555) | 13 | 7 | 6 | 6 | 4 | 5 | 7 | -5 | 43 |
| 13 | 禾元生物(688765) | 15 | 8 | 5 | 4 | 4 | 4 | 5 | -8 | 37 |
| 14 | 游族网络(002174) | 14 | 4 | 3 | 3 | 5 | 4 | 7 | -8 | 32 |
| 15 | 北纬科技(002148) | 8 | 3 | 3 | 2 | 4 | 4 | 6 | -10 | 20 |
5. Top 10 Stocks in Detail
51 恒瑞医药600276Overall No. 1, priority deep-dive · Hengrui Medicine · Shanghai main board
- Related news: Announcement on the evening of 11-15: 3 drugs (泽美妥司他片 zemaitostate tablets, 鲁兹诺雷钠片 luzhinore sodium tablets, 恒格列净瑞格列汀二甲双胍缓释片(II)) included in medical insurance for the first time; 瑞康曲妥珠单抗 (Ruikang trastuzumab) reimbursement indication expanded; 达尔西利 (Darsirib) renewed + new indication added; plus 7 renewals; combined 2025 sales of the above drugs ~RMB 6.951 billion, ~RMB 6.860 billion for the first three quarters of 2026 (CLS9、JRJ2).
- Positive logic: Direct positive but mostly already priced in. Medical-insurance negotiation trades price for volume; the new catalogue takes effect only on 2027-01-01, contributing almost nothing to 2026 current-period earnings; for renewed products it is price continuation, for the 3 first-time inclusions it is an access catalyst. What moves is valuation and sentiment, not the current-quarter report.
- Industry-branch stage: Innovative-drug payment-side expansion is a mid-term narrative (second year of the commercial-insurance catalogue, dual-catalogue linkage); currently at the early fermentation stage of a "policy-event-driven" move, with no limit-up ladder and no core-heavyweight sentiment premium — Hengrui itself is the core heavyweight.
- Fundamentals check: Absolute innovative-drug leader. 2025 revenue RMB 31.629 billion (+13.0%), net profit attributable to parent RMB 7.711 billion (+21.7%); first three quarters of 2026 revenue RMB 24.409 billion (+5.3%), net profit attributable to parent RMB 6.923 billion (+20.4%), Q3 single-quarter net profit +88.9%; gross margin 86.8%, cash RMB 43.45 billion, debt ratio 12.2%, 9M operating cash flow +RMB 7.844 billion; innovative-drug revenue already over 60%. Healthiest balance sheet on the entire list.
- Industry position: Overall innovative-drug leader (pipeline breadth + BD monetization both top tier, 2025 BD revenue RMB 3.392 billion).
- Technicals / sentiment: Main board ±10%; sold off with pharma on Friday, at an oversold position; market cap ~RMB 319 billion, largest institutional capacity, suitable for large funds both defensive and offensive. Note that STAR peers (Baili Tianheng/Junshi) gapping up excessively on 20cm could divert main-board funds.
- Final call: priority deep-dive. Weekend announcement confirmed + leader + hardest financials, the most tradable target in the innovative-drug branch; but "sell the good-news realization" is the historical pattern of medical-insurance-catalogue moves — if it gaps up over 3% at auction and shows no absorption within 30 minutes, downgrade to watch only.
52 中国海油CNOOC / 600938Overall No. 3, priority deep-dive (defense) · Shanghai main board
- Related news: On 11-15, Iran's 6 drones attacked the radar of the US military base in Riffa, Bahrain; Iran warned of expanding strikes to US bases in Europe (The Paper7); but Brent's grey market was only +0.38% after the 11-15 attack, and Caixin reported on 11-14 that global crude supply is back in surplus, with WTI/Brent down 14%-18% last week from end-October (Caixin Weekly14).
- Positive logic: Indirect (event kicker) + direct (earnings already materializing). Oil-price elasticity flows straight into the report: 9M26 net profit +16.8% mainly benefited from the Brent price center moving up vs 2025 (~USD 70) — note "USD 94" is the YTD-average basis, and the spot price has already fallen 14-18% from end-October (Caixin Weekly); the two are not contradictory; the Middle East conflict provides a sentiment premium, not a supply-demand shock.
- Industry-branch stage: The oil & gas chain showed "internal divergence, defensive position established" on Friday: CNOOC (600938) +2.05% was the only decent gain among big caps, 岳阳兴长 (Yueyang Xingchang, 000819) limit-up, while the oil-shipping elasticity position COSCO Shipping Energy (600026) -2.21% was abandoned — the branch is in "divergence", not "main upward wave".
- Fundamentals check: 2025 revenue RMB 398.2 billion, net profit attributable to parent RMB 122.08 billion; first three quarters of 2026 revenue RMB 355.6 billion (+13.8%), net profit attributable to parent RMB 119.12 billion (+16.8%); per-barrel cost in the industry's lowest tier; PE (TTM) ~10.5x; dividend per share ~RMB 1.292 over the past 12 months (2025 final RMB 0.4788 + 2026 interim RMB 0.8132), a TTM dividend yield of ~4.2% vs Friday's close of RMB 30.85 (trailing-12-month dividend basis, Eastmoney dividend interface). Thickest financial and valuation safety cushion on the list.
- Industry position: Absolute leader in offshore oil & gas production (market cap ~RMB 1.47 trillion).
- Technicals / sentiment: Main board ±10%; on Friday's ice-point day a RMB 1.44 trillion market cap closed green on volume, the real destination of funds rotating to low positions; if the auction stays strong on Monday, its "defensive core heavyweight" status is confirmed.
- Final call: priority deep-dive (defensive position). In an ebb period and ahead of NVIDIA earnings, its "~10.5x + ~4.2% dividend" combo is the ballast; the risk is the supply-surplus oil logic — it loses elasticity as soon as the event cools. It is a "hold for the dividend and pocket the event money" stock, not an offensive stock.
53 源杰科技688498Overall No. 2, watch closely · Yuanjie Technology · STAR Market · ±20%
- Related news: Announcement on the evening of 11-13: won a RMB 1.744 billion (ex-tax) high-power laser-diode chip order from Customer B (CLS3); the stock fell -11.76% single-day on Friday to close at RMB 673.10, market cap ~RMB 82.7 billion; the market speculates Customer B is related to the overseas computing-power chain, but the company exempted disclosure of the customer identity under confidential procedures — "related to the overseas computing-power chain" is market speculation, not an announcement fact.
- Positive logic: Direct order positive, huge elasticity. RMB 1.744 billion ≈ 108% of 9M26 revenue (RMB 1.609 billion), 2.9x full-year 2025 revenue; the company announced two capacity expansions in 2026 totaling over RMB 5.5 billion (Aug: RMB 4.268 billion semiconductor industrial park + Feb: RMB 1.251 billion base phase II, Sina Finance16), and the Q3 earnings call said "end customers may also become direct customers in the future", pointing to high-power CW/EML light sources for AI optical modules — but delivery is mostly after 2027, so the elasticity lands far out.
- Industry-branch stage: The optical communications / optical module sector overall is in the third day of ebb (Friday: 中际旭创 (Zhongji Innolight, 300308) -8.39%, 新易盛 (Eoptolink, 300502) -8.76%, 天孚通信 (300394) -10.94%); Yuanjie is a lone case of "single-stock logic against sector trend"; no ladder, no follower limit-ups — it is a standalone order-driven move.
- Fundamentals check: Scarce optical-chip IDM leader (one of few in China mass-producing 25G/100G EML; high-speed optical chips previously monopolized by Lumentum/Broadcom). 2025 revenue RMB 601 million (+138.5%), net profit attributable to parent RMB 191 million; first three quarters of 2026 revenue RMB 1.609 billion (+319.8%), net profit attributable to parent RMB 1.024 billion (+866.9%), gross margin 81.7%; data-center revenue RMB 774 million in 2026H1 (+640%). Genuinely rapid reported growth; hidden concerns are accounts receivable +151.7% YoY and PE (TTM) ~75x.
- Industry position: Niche leader (a scarce A-share optical-chip design + IDM name, "the former stock king").
- Technicals / sentiment: STAR Market ±20%; a big-volume -11.76% plunge on Friday followed by good news, huge long-short disagreement; Monday's auction is the showdown between "order logic beats sector ebb" and "good-news distribution".
- Final call: watch closely (auction decides). Gap up 3%+ and hold above Friday's low for 30 minutes with active volume → order logic holds; open lower or turn green-negative 15 minutes after a gap-up → the sector drag wins, delete. 75x PE + anonymous customer do not support chasing; only right-side follow after auction confirmation.
54 中国稀土000831Overall No. 4, watch closely · China Rare Earth · Shenzhen main board
- Related news: Announcement on 11-15: plans to issue shares to purchase 51% of Zhongxi (Liangshan) Rare Earth and raise supporting funds, issue price RMB 39.41/share (~17% discount to the RMB 47.59 pre-suspension price), resumes trading 11-16; the target's core asset is the Maoniuping rare earth mine (REO ~11.46 million tonnes, No. 2 in China for light rare earths), net profit RMB 511/819/674 million in 2024/2025/2026H1 (NBD10).
- Positive logic: Direct (asset injection accretion). The target's 2025 net profit is 4.75x the listed company's (RMB 173 million); the 51% stake corresponds to an annual net-profit contribution of ~RMB 420 million+, a major accretion; it is also the group's move to honor its 2027 commitment to resolve horizontal competition. The first trade-council meeting (11-13) keeps communication going; the rare-earth export-control suspension (to 2026-11-10, per the Ministry of Commerce's April statement, Sina Finance17) has expired — whether controls resume (bullish for domestic price expectations, bearish for export volumes) or talks extend is a two-way scenario with an undetermined direction; do not trade it as one-way bullish.
- Industry-branch stage: Rare earths have no running limit-up ladder; this is a "restructuring-resumption event-driven" move; Northern Rare Earth (600111) is the sector core heavyweight.
- Fundamentals check: Listed company 2025 revenue RMB 3.182 billion, net profit attributable to parent RMB 173 million (turnaround, +160%); first three quarters of 2026 net profit attributable to parent RMB 408 million (+112%), but the Q3 single-quarter +461.7% relies mainly on rare-earth price rises plus reversal of inventory write-down provisions (earnings quality needs a discount); debt ratio only 9.8%, 9M operating cash flow +RMB 674 million (+469%). Expensive valuation: PE (TTM) ~130x, PB ~9.7x.
- Industry position: Listed platform for medium/heavy rare-earth smelting & separation; after the injection it becomes an integrated "mining-beneficiation-smelting-processing" player.
- Technicals / sentiment: Main board ±10%; suspended for 2 weeks + no new rare-earth negative news over the weekend, so resumption is most likely one-way sealed or gap up over 7%; if the gap-up is excessive (e.g. 8%+ with the seal opening on huge volume), downgrade directly to watch only — the first bite of a restructuring resumption usually cannot be had and must not be chased.
- Final call: watch closely. The assets are real and the accretion is real, but 130x PE + undetermined pricing + the rare-earth price cycle make triple uncertainty; it is only worth participating if "strong absorption after the seal opens and sector follows (Northern Rare Earth volumes up)"; otherwise just watch.
55 百利天恒688506Overall No. 5, watch closely · Baili Tianheng · STAR Market · ±20%
- Related news: Announcement on 11-15: the world's first EGFR×HER3 bispecific ADC (iza-bren/宜泽康® Yizekang, approved in June) was included in the 2026 medical-insurance catalogue in its first launch year via the "pre-declaration" mechanism, reimbursement limited to recurrent/metastatic nasopharyngeal carcinoma after failure of at least second-line chemotherapy and PD-1/PD-L1 therapy (CLS18).
- Positive logic: Indirect + access catalyst. The medical-insurance reimbursement scope is narrow (single nasopharyngeal-carcinoma indication), with small impact on current-period revenue; the real earnings variable is the cadence of BMS-license milestones (2023-12 agreement framework up to USD 8.4 billion; by 2025-10, upfront + milestones of over USD 1 billion already recognized, Tencent News19) and global Phase III data. First-year medical-insurance inclusion raises the certainty of domestic commercialization.
- Industry-branch stage: In sync with the innovative-drug branch; the high-elasticity target (STAR 20cm).
- Fundamentals check: 2025 revenue RMB 2.520 billion (-56.7%), net profit attributable to parent -RMB 1.054 billion; first three quarters of 2026 revenue RMB 2.094 billion (Q3 single-quarter ~RMB 1.9 billion, inferred to be the BMS milestone payment — this inference is not confirmed by the company and needs verification), net profit attributable to parent -RMB 705 million; 9M R&D expense RMB 2.045 billion (98% ratio); operating cash flow -RMB 2.168 billion, debt ratio 59.1%, burning cash and reliant on continued BMS payments. Market cap ~RMB 103.2 billion.
- Industry position: The only listed global FIC bispecific ADC, highest pipeline deliverability in the innovative-drug group (BD cash flow as backing).
- Technicals / sentiment: STAR Market ±20%; if innovative drugs ferment, it is the highest-elasticity target; unprofitable + highly leveraged means extreme volatility.
- Final call: watch closely. Buying it is buying the combination of "global FIC + medical-insurance access + BMS monetization", not current earnings; only a 10%+ auction gap-up that does not fade within 15 minutes shows fund recognition — otherwise wait for a pullback.
56 恺英网络002517Overall No. 6, watch closely · Kaiying Network · Shenzhen main board
- Related news: On 11-15 BLG beat GEN 3:1 to win the League of Legends S16 championship, LPL champions again after five years, Bilibili giving all members premium membership (Eastmoney13); the gaming branch was Friday's only survivor alongside AI short drama.
- Positive logic: Indirect (industry sentiment) + direct (own earnings). The esports championship lifts sector attention and sentiment, but Kaiying itself does not depend on this event — its logic is "gaming-branch catch-up + real earnings": "Blazing Awakening" contributed ~RMB 3.2 billion revenue in 9M26 (Phoenix Finance20 citing company financials), and "Three Kingdoms: Tianxia Guixin" launched in October.
- Industry-branch stage: Gaming/media is a "running theme": Wentou Holdings (600715) with 10 limit-ups in 18 days is the sentiment top; Kaiying -1.90% on Friday, a low-position catch-up spot.
- Fundamentals check: 2025 revenue RMB 5.325 billion, net profit attributable to parent RMB 1.904 billion (+16.9%); first three quarters of 2026 revenue RMB 7.258 billion (+78.1%), net profit attributable to parent RMB 2.069 billion (+30.7%), gross margin 76.7%, operating cash flow RMB 2.002 billion; PE (TTM) ~14.3x. Note Q3 single-quarter net profit only +1.22% (early sign of revenue-up-profit-not), and "Blazing Awakening" ~RMB 3.2 billion ≈ 44% of first-three-quarter revenue (32/72.58 estimate).
- Industry position: Gaming sector's best on both earnings and valuation (niche leader).
- Technicals / sentiment: Main board ±10%; no consecutive-limit-up baggage, institutions can hold; if gaming ferments on Monday, it is the stock you "can board" (Wentou/Beiwei are not boardable).
- Final call: watch closely. If the branch holds (Wentou no nuclear button + low-position 1-to-2 appear), it is the gaming branch's first choice; if not, it falls back to the ~14x PE earnings floor, with controllable downside.
57 中远海能600026Overall No. 7, watch only · COSCO Shipping Energy · Shanghai main board
- Related news: Same as CNOOC (Middle East event); oil shipping is the most direct elasticity play on the Middle East situation (VLCC rate risk premium).
- Positive logic: Direct (event-sensitive). Middle East tension → Strait of Hormuz transit risk + shadow-fleet sanctions → effective capacity contraction → rate elasticity; 2026 earnings already materializing (9M26 net profit +171.9%).
- Fundamentals check: 2025 revenue RMB 23.89 billion, net profit attributable to parent RMB 4.04 billion; first three quarters of 2026 revenue RMB 25.24 billion (+47.0%), net profit attributable to parent RMB 7.39 billion (+171.9%), gross margin 40.8%; PE (TTM) ~10.3x, TTM dividend yield ~4.0%; debt ratio 47.7%, highest in the oil & gas group. Strong cyclical.
- Technicals / sentiment: Main board ±10%; Friday -2.21% — Friday's recap already characterized "elasticity position abandoned"; recovery needs double confirmation of "gap-up on auction volume + 3 or more sector limit-ups".
- Final call: watch only. The cleanest logic and biggest elasticity, but Friday funds voted with their feet for the defensive position (CNOOC); if the oil & gas chain really explodes on Monday, it will be the fiercest follower — there will still be time to board then.
58 君实生物688180Overall No. 8, watch only · Junshi Biosciences · STAR Market · ±20%
- Related news: Announcement on 11-15: Toripalimab (拓益® Touyi) plus disitamab vedotin for HER2-expressing urothelial carcinoma added as a new medical-insurance indication; all 13 indications now included (company announcement21).
- Positive logic: Direct and materializing. PD-1 is ~80% of revenue; the volume-for-price logic has been validated by "9M26 revenue +39.2%, loss narrowing, operating cash flow turning positive"; the new indication is continuation, not a sudden change.
- Fundamentals check: 2025 revenue RMB 2.498 billion, net profit attributable to parent -RMB 875 million; first three quarters of 2026 revenue RMB 2.513 billion (+39.2%), net profit attributable to parent -RMB 149 million (loss greatly narrowed), gross margin 82.7%; debt ratio 59.6%, low cash/interest-bearing-debt ratio. Unprofitable.
- Technicals / sentiment: STAR Market ±20%; the "materializing" name within the innovative-drug branch, with elasticity and risk both below Baili Tianheng.
- Final call: watch only. The materialization is real and the improvement is real, but unprofitable + high leverage make it just an observation sample within the branch; if you must play innovative drugs, main-board Hengrui is steadier and Baili Tianheng has bigger elasticity — Junshi sits in the middle, neither here nor there.
59 中海油服COSL / 601808Overall No. 9, watch only · Shanghai main board
- Related news: Same as CNOOC; the offshore oilfield-services leader, benefiting from parent and industry capex.
- Positive logic: Indirect (longest transmission chain): day rates and contracts lag oil prices; 9M26 net profit only +0.7%, revenue up but profit not, the weakest event elasticity among the five oil names.
- Fundamentals check: 2025 revenue RMB 50.28 billion, net profit attributable to parent RMB 3.84 billion (+22.5%); first three quarters of 2026 revenue RMB 35.73 billion (+2.5%), net profit attributable to parent RMB 3.23 billion (+0.7%); 9M operating cash flow only RMB 1.9 billion (weakening); debt ratio 41.6%; TTM dividend yield ~2.3%. PE (TTM) ~15.2x.
- Final call: watch only. Steady but bland; Friday +0.41% already reflected "follower" status; for oil & gas exposure just do CNOOC (defense) and COSCO Shipping Energy (elasticity) — oilfield services sits in the middle with neither end.
510 复星医药600196Overall No. 10, watch only · Fosun Pharma · Shanghai main board
- Related news: Announcement on 11-15: 5 drugs included (Hanshuang/serplulimab first inclusion is the largest marginal addition, Futuoning/Fumaining new reimbursement indications, Fukeshu moved to the regular catalogue); involved drugs 2025 sales RMB 2.234 billion (~5.36% of group revenue) (10jqka citing announcement22).
- Positive logic: Indirect, mildly positive. Involved drugs are only 5% of revenue, and effective only in 2027; at the group level, generic-drug centralized-procurement pressure and investment-income swings are the main earnings variables — the medical-insurance catalyst is almost invisible on the report.
- Fundamentals check: 2025 revenue RMB 41.662 billion, net profit attributable to parent RMB 3.371 billion (+21.7%); first three quarters of 2026 revenue RMB 30.463 billion (+3.6%), net profit attributable to parent RMB 2.667 billion (+5.7%); goodwill RMB 10.76 billion (~21% of net profit attributable to parent); short-term borrowings RMB 15.49 billion vs cash RMB 13.3 billion; PE ~18x, PB ~1.2x.
- Final call: watch only. Low valuation + low debt cost form a floor, but innovative-drug elasticity is diluted by the huge base, and goodwill plus short-term debt cap the upside; it is a "bond-like asset" within pharma, not a catalyst asset.
6. Pass List
| Code | Name | Concept | Why associated | Pass reason | Keep watching? |
|---|---|---|---|---|---|
| 002174 | 游族网络 | Storage trading + gaming | RMB 1.428 billion flash order + BLG championship gaming sentiment | Announcement explicitly states minimal revenue impact under the net method — just pass-through trading; gaming main business 2025 loss of RMB 347 million, another RMB 111 million single-quarter loss in Q3, 9M operating cash flow -RMB 651 million (advance-payment risk already visible); concept mash-up easily pulled up by quant sentiment, extremely high relay risk | Watch (sentiment thermometer only, no relay) |
| 002148 | 北纬科技 | Gaming / short drama | 3-limit-up height + gaming ETF holdings | PE (TTM) ~7700x; 9M26 net profit only RMB 5.92 million, Q3 -60%, operating cash flow negative for consecutive periods; no substantive revenue from gaming/short drama; after Tianpu's suspension it became the height banner, but fundamentals cannot support a fourth limit-up | Weathervane only (its limit-up = sentiment repair, nuclear button = continued ebb) |
| 300528 | 幸福蓝海 | AI short drama / film | Friday 20cm limit-up, AI comic-drama narrative | Cinema main business ~79% of revenue, first three quarters of 2026 revenue -20%, losses expanded 8x, six consecutive loss-making years, debt ratio ~78%, PB 19x; AI short-drama revenue share negligible (not separately disclosed) | Watch (branch sentiment sample, no buying) |
| 600715 | 文投控股 | AI comic-drama overall leader | 10 limit-ups in 18 days | Company self-disclosed AI comic-drama revenue share of only ~2.57% (unaudited); sentiment-top signature, Friday's recap already said "do not take the last baton of the overall leader" | Watch (branch life-or-death signal only) |
| 603396 | 金辰股份 | Photovoltaic / HJT concept | 3 limit-ups + SINGULUS report association | Company risk warning on the evening of 11-15: unrelated to the reported matters, no substantive business dealings with SINGULUS SOLAR (that subsidiary had zero revenue in Jan-Oct); buyback + TGV glass-substrate packaging concept insufficient support | No |
| 002129 | TCL 中环 | Semiconductor silicon wafer restructuring | Resumption + acquiring wafer leader | Acquisition real but accretion only ~RMB 100 million-level, a drop in the bucket vs the -RMB 4.557 billion main-business loss (9M26); debt ratio 73.4% rising quarter by quarter; PV wafer gross margin still negative (2026 Q3 gross margin -7.3%); share issuance dilution | Watch (no chasing the resumption pop) |
| 605255 | 天普股份 | Auto parts / compute chips | 4 consecutive limit-ups | Suspended for verification from 11-16, untradable; high catch-down risk after resumption | No (no trading value before resumption) |
| 002555 | 三七互娱 | Gaming (BLG sentiment) | Gaming leader + championship sentiment | 9M26 ex-non-recurring ~-47%, Q3 single-quarter loss of RMB 506 million (including investment swings), operating cash flow -60%; user-buying model entering a pressured stock phase, the championship cannot save the report | Watch (sector core-heavyweight reference only) |
| 688765 | 禾元生物 | Innovative drugs (-U) | World's first rice-derived recombinant human albumin into medical insurance | 9M26 revenue only RMB 28 million, annual losses over RMB 100 million, RMB 1.4 billion construction-in-progress with ongoing capex; the 0-to-1 story is real but there are no current earnings, and it already front-ran +8.8% on Friday | Watch (branch sentiment sample only, do not participate) |
| 603366/600327 | 日出东方 (Sunrise East) / 大东方 (Great East) | Mysticism high-flags | Earlier consecutive limit-ups | Regulatory letter + ebb confirmed; Friday Great East (600327) limit-down; the bounce is an escape window | No |
| — | Commercial spaceflight / low-altitude concept | Starship recovery / CE-25A first flight | SpaceX chopsticks catch + electric aircraft first flight | Remote mapping, no direct A-share orders/supply evidence; historically high probability of a one-day pop | No |
| — | Energy-storage battery expansion chain | 15th Five-Year storage plan | Policy release | The plan's main tone is "guard against blind expansion, implement lithium-battery industry control" — a constraint on expansion, not encouragement; direction bearish | No |
7. Intra-Branch Ranking
7.1 Innovative Drugs (Medical-Insurance Dual Catalogues)
| Rank | Stock | Board | Role | Directness | Fundamentals support | Trading recognizability | Conclusion |
|---|---|---|---|---|---|---|---|
| 1 | 恒瑞医药(600276) | Shanghai main board | Core heavyweight / overall leader | High (3 first-time inclusions + 7 renewals, involved sales RMB 6.951 billion) | Strongest (net profit +20.4%, cash RMB 43.4 billion) | Highest (RMB 319 billion capacity) | hardest stock, priority deep-dive |
| 2 | 百利天恒(688506) | STAR Market | Elasticity leader | Medium (FIC access catalyst) | Medium (unprofitable, cash flow -RMB 2.17 billion, but backed by BMS USD 8.4 billion) | High (20cm) | Top elasticity pick, for high risk appetite |
| 3 | 君实生物(688180) | STAR Market | Niche fulfiller | High (all 13 indications included, materializing) | Medium (loss narrowing + cash flow positive) | Medium | Observation sample |
| 4 | 复星医药(600196) | Shanghai main board | Low-valuation defense | Low (involved drugs 5% of revenue) | Medium (18x PE, goodwill pressure) | Medium | Bond-like observation |
| 5 | 禾元生物(688765) | STAR Market (-U) | Pure expectation | Medium (exclusive access) | Weak (annual revenue RMB 28 million) | Low | watch only |
Follower note: Zelgen (泽璟制药), Allist (艾力斯), Dizal (迪哲医药) et al. were not verified one by one by this group; if funds scoop them to limit-up at Monday's auction, that is branch follow-on and not recommended in this list. Who Passes: Heyuan Biotech (unprofitable small cap), any target lifted purely on the "innovative drug concept" without an announcement.
7.2 Oil & Gas / Oil Shipping (Middle East Event + Dividends)
| Rank | Stock | Board | Role | Directness | Fundamentals support | Trading recognizability | Conclusion |
|---|---|---|---|---|---|---|---|
| 1 | 中国海油(600938) | Shanghai main board | Defensive core heavyweight | Medium (oil-price elasticity, 9M26 net profit +16.8% materializing) | Strongest (10.5x / dividend ~4.2%) | Highest (RMB 1.47 trillion, Friday's only big-cap volume gain closing green) | hardest, defensive first choice |
| 2 | 中远海能(600026) | Shanghai main board | Elasticity play | High (direct rate beneficiary) | Strong (+172%, 10.3x / dividend 4.0%) | High | watch only, wait for double confirmation |
| 3 | 中海油服(601808) | Shanghai main board | Follower | Low (longest transmission chain) | Medium (+0.7%, revenue up profit not) | Medium | watch only |
| — | 岳阳兴长(000819) | Shenzhen main board | Back-row sentiment | Low | Weak | Low (Friday 1 limit-up) | Pass (lone seed, no relay) |
Followers: Yueyang Xingchang et al. first-limit-up sentiment plays; who Passes: Heshun Petroleum (和顺石油, 603353), Hongtong Gas (洪通燃气, 605169) et al. Friday's broken-limit-up sentiment plays.
7.3 Gaming / Esports / AI Short Drama (Running Theme)
| Rank | Stock | Board | Role | Directness | Fundamentals support | Trading recognizability | Conclusion |
|---|---|---|---|---|---|---|---|
| 1 | 恺英网络(002517) | Shenzhen main board | Real-earnings catch-up | Medium (BLG sentiment + own hit title) | Strongest (revenue +78% / net profit +31%, 14x) | High | branch's first-choice tradable |
| 2 | 文投控股(600715) | Shanghai main board | Overall leader (sentiment top) | Low (self-disclosed revenue share 2.57%) | Weak | Highest (10 limit-ups in 18 days) | watch only, branch life-or-death signal |
| 3 | 金逸影视(002905)/横店影视(603103)/中国电影(600977) | Shenzhen/Shanghai main board | Low-position 1-to-2 watch pool | Low | Cinema fundamentals weak | Medium | watch, only advance confirms |
| 4 | 三七互娱(002555) | Shenzhen main board | Core heavyweight (weakening) | Low | Weak (ex-non-recurring -47%) | Medium | watch only |
Who Passes: Beiwei Technology (002148, PE 7700x pure sentiment), Xingfu Lanhai (300528, six consecutive loss-making years).
8. Monday Opening Verification Signals
Broad market (top priority): Friday's ice point (advancement rate 19%, 33 limit-downs); Monday's first signal is whether the Shanghai Composite can reclaim 3647 (Friday's breakdown point) and whether ChiNext can stop falling; if the Shanghai Composite opens down over 0.5% and cannot recover within 30 minutes, all branch verification points automatically invalidate — stay in cash and observe. The FX reserve-requirement-ratio hike to 6% taking effect + the reverse repo rolled at a smaller size make liquidity expectations neutral-to-tight.
Auction signals (9:15-9:25):
- Innovative drugs: the gap-up magnitude of Hengrui (600276) and Baili Tianheng (688506) — gap-up ≤3% with moderate auction volume = healthy; 3 or more pharma limit-ups in the sector (or two 20cm ones) = branch confirmed; Hengrui gap-up 5%+ and turning green-negative before 9:35 = profit-taking dominates, whole branch downgraded.
- Oil & gas: whether CNOOC (600938) stays strong at auction (green + volume); the Asian-session Brent catch-up move to Saturday's attack (Friday's print 93.99; if the Asian session rises over 2%, the event is being re-priced).
- Yuanjie Technology (688498): gap-up 3%+ and holding above Friday's low for 30 minutes = order logic wins; open lower or turn green-negative 15 minutes after gap-up = sector drag wins, delete.
- China Rare Earth (000831): most likely huge one-way orders / big gap-up; seal opening on huge volume is the danger; whether Northern Rare Earth (600111) follows with volume is the branch confirmation signal.
- Gaming: whether Wentou Holdings (600715) gets the nuclear button at auction (open down 5%+) = whole branch downgraded; Beiwei Technology (002148) 3-to-4 and low-position cinema 1-to-2 (Jinyi Cinema (002905) / Hengdian Entertainment (603103)) are the sentiment-rebuilding signals.
Sector signals: 3 or more fast limit-ups in the same branch = ladder confirmed; core-heavyweight volume (Hengrui / CNOOC / Kaiying) = real money; second/third-limit-up ladder appearing = sentiment repair; yesterday's strong themes (computing power / storage) still leading the decline = the ebb has not ended, new-theme height is capped.
Single-stock signals: absorption in the first 5 minutes, fast limit-up without huge volume, large-order net inflows; being out-positioned by a stronger same-branch stock (e.g. Junshi stronger than Baili) = swap signal.
Risk signals (exit immediately if triggered): ① the computing-power chain opens lower and keeps selling (the mapping of NVIDIA -13% weekly + SOX -3.43% is unfinished; no one catches the falling knife before NVDA earnings Tuesday); ② innovative drugs gap up then fade, all turning green-negative; ③ Iran situation cools (ceasefire / negotiation language) = oil & gas event position exits immediately; ④ Wentou Holdings nuclear button crashes gaming; ⑤ a low-volume index rebound failing at 3647 = a mid-decline continuation.
9. Final Recommendations
① The 5 Most Worthy Stocks Today (sorted by tradeability, not by overall score)
| Rank | Stock | Branch | Reason | Biggest risk | Tomorrow's verification |
|---|---|---|---|---|---|
| 1 | 恒瑞医药(600276, Shanghai main board) | Innovative drugs | Weekend announcement confirmed (3 first-time inclusions + 7 renewals) + absolute innovative-drug leader + 9M26 net profit +20.4% + RMB 43.4 billion cash; the only large-capacity exit for big money on the ice-point day | Medical insurance effective only in 2027, sell-the-realization; 41x PE gap-up gets smashed | Gap-up ≤3% with 30-minute absorption; 3 or more sector limit-ups |
| 2 | 中国海油(600938, Shanghai main board) | Oil & gas defense | ~10.5x + ~4.2% dividend safety cushion, 9M26 net profit +16.8% materializing, Friday's only big-cap volume gain closing green, Middle East event kicker | Oil supply surplus, loses elasticity as the event cools | Green at auction + Brent holding USD 94 in Asian session; cut exposure if it falls back below 30.5 |
| 3 | 源杰科技(688498, STAR Market ±20%) | Optical chips | RMB 1.744 billion order = 108% of 9M26 revenue, scarce IDM leader + genuinely rapid earnings growth (+867%) | 75x PE + anonymous customer + sector ebb, already -11.76% Friday | Auction gap-up 3%+ and holding above Friday's low for 30 minutes, else delete |
| 4 | 恺英网络(002517, Shenzhen main board) | Gaming / esports | BLG championship fermenting over the weekend + own "Blazing Awakening" ~RMB 3.2 billion revenue in 9M (Phoenix citing financials), revenue +78% / 14x, unmoved Friday with catch-up room | Hit-title concentration ~44% (estimate); one-day gaming sentiment | Wentou Holdings (600715) no nuclear button + low-position cinema 1-to-2 appear |
| 5 | 中国稀土(000831, Shenzhen main board) | Rare-earth restructuring | Injecting 51% of Zhongxi (Liangshan) (target 2025 net profit RMB 819 million = 4.75x the listed company) + debt ratio only 9.8% + China-US consultation window | 130x PE; pricing undetermined; most likely unbuyable or gap-up too large | Resumption seal order / absorption after seal opens; Northern Rare Earth (600111) volume follow; gap-up 8%+ with seal opening on huge volume = watch only |
Alternate: Baili Tianheng (688506, STAR Market) — the elasticity king of innovative drugs, for high risk appetite after auction confirmation.
② The 3 Strongest Branches Today
| Rank | Branch | Core catalyst | Durability | Representative stocks |
|---|---|---|---|---|
| 1 | Innovative drugs (medical-insurance dual catalogues) | 51 first-class innovative drugs a record high + CAR-T first medical-insurance entry + 19 concentrated disclosures | Medium (2027 effective; short-term sentiment + mid-term payment expansion) | 恒瑞医药(600276) 、百利天恒(688506) |
| 2 | Oil & gas defense (Middle East event) | Iran's attack on the US military base in Bahrain escalates | Short-medium (event position, exit on ceasefire) | 中国海油(600938) 、中远海能(600026) |
| 3 | Gaming / esports / AI short drama | BLG S16 championship + Friday's only survivor continuing | Short (sentiment, watch low-position ladder) | 恺英网络(002517) 、文投控股(600715, risk) |
③ Directions Not to Chase Today
- The entire computing-hardware chain (optical modules / PCB / servers / storage): NVIDIA CEO resignation + -13% weekly + SOX -3.43%, funds de-risking ahead of NVDA earnings Tuesday; the third day of ebb — do not catch the falling knife (continuation of Friday's recap conclusion).
- Pure-sentiment high-flags: Wentou Holdings (600715, 10 limit-ups in 18 days + revenue share 2.57%), Beiwei Technology (002148, PE 7700x), Xingfu Lanhai (300528, six consecutive loss-making years) — relay = catching the knife.
- Yoozoo Network (002174): net-method order does not enter the report + main-business losses + deteriorating advance-payment cash flow; the dual concept is a quant incubator.
- TCL Zhonghuan (002129): the acquisition good news is real but its magnitude is drowned by the -RMB 4.557 billion main-business loss, 73.4% debt ratio; no chasing the resumption pop.
- Storage expansion chain: the "15th Five-Year" plan's main tone is guarding against blind expansion — direction bearish.
- Commercial spaceflight / low-altitude / silver concepts: remote mapping, no direct A-share order evidence, high probability of a one-day pop.
④ Final One-Line Judgment
A "news-driven-repair observation day" after the ice point: Monday's strongest new catalyst is innovative drugs ignited by the medical-insurance dual catalogues (Hengrui as the core heavyweight, Baili Tianheng as the elasticity play); for defensive positioning watch CNOOC's (600938) dividend floor; for sentiment positioning watch low-position gaming catch-up (Kaiying Network); Yuanjie Technology's (688498) RMB 1.744 billion order will be settled by the auction; keep avoiding the computing-power chain until NVDA earnings land, and discount all positions until the Shanghai Composite reclaims 3647.
⚠️ Data-sourcing notes for this report: ① Quotes/financials were pulled this morning by three fundamentals sub-agents via akshare (Eastmoney earnings/dividend interfaces + Tencent/Sina quotes), covering the 2025 annual report + 2026 Q3 report; total market cap is estimated as closing price × total shares. ② Friday's recap recorded Eastmoney push2 sector interface 502 errors and the 龙虎榜 (dragon-tiger list) interface returning None; this report no longer relies on those two interfaces, so dragon-tiger / sector fund-flow data is missing and not included in the body. ③ The recognition nature of Baili Tianheng's Q3 single-quarter revenue of ~RMB 1.9 billion (inferred to be the BMS milestone payment) is not confirmed by the company and is flagged in the body. ④ Brent data-basis discrepancy: Caixin Weekly says WTI/Brent fell 14-18% last week from end-October, while the sub-agent got USD 93.99 intraday on 11-13 + grey market +0.38% after the attack; the body presents both side by side. ⑤ Two corrections after risk-auditor QC: CNOOC total score 66→63 (component-sum arithmetic error, rank swapped with Yuanjie); its TTM dividend yield 6.3%→4.2% (the original basis double-counted the 2025 interim dividend; corrected to trailing 12 months: 2025 final RMB 0.4788 + 2026 interim RMB 0.8132 ÷ RMB 30.85).
⚠️ Risk warning: this list is only a pre-market information roundup and observation aid, and does not constitute investment advice. A-share volatility risk is extremely high; automatically generated content may carry information timeliness gaps or industry-chain mapping errors, and must not be used directly as a trading basis.
Sources22
Every external link cited in the body, numbered in order of appearance. · 16 domains
- 1Qiushi.comqstheory.cn
- 2JRJfinance.jrj.com.cn
- 3CLScls.cn
- 4TMTPosttmtpost.com
- 5JW View (US close)jwview.com
- 6Jin10flash.jin10.com
- 7The Paperthepaper.cn
- 8CLScls.cn
- 9CLS weekend roundupcls.cn
- 10Company announcement (via NBD)sfccn.com
- 11CLSm.cls.cn
- 1210jqkam.10jqka.com.cn
- 13Eastmoneywap.eastmoney.com
- 14Caixin Weeklyweekly.caixin.com
- 15Jiemianm.jiemian.com
- 16Sina Financefinance.sina.com.cn
- 17Sina Financefinance.sina.com.cn
- 18CLScls.cn
- 19Tencent Newsnews.qq.com
- 20Phoenix Financefinance.ifeng.com
- 21company announcementfinance.jrj.com.cn
- 2210jqka citing announcementm.10jqka.com.cn